🇺🇸 FDA
Patent

US 11951133

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

granted A61KA61K2039/5152A61K2239/49

Quick answer

US patent 11951133 (3-substituted piperidine compounds for Cbl-b inhibition, and use thereof) held by NURIX THERAPEUTICS, INC. expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K2039/5152, A61K2239/49, A61K2239/50, A61K2239/55